Trial record 2 of 2 for:    AZD2820

To Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01332214
Recruitment Status : Completed
First Posted : April 11, 2011
Last Update Posted : November 21, 2011
Information provided by (Responsible Party):

Brief Summary:
This is a randomised, single-blind, placebo-controlled Phase I study to investigate the safety, tolerability and pharmacokinetics after administration of single doses of AZD2820 to healthy male subjects.

Condition or disease Intervention/treatment Phase
Healthy Drug: AZD2820 Drug: Placebo Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 90 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Basic Science
Official Title: A Randomised, Single-blind, Placebo-controlled Single-centre Phase I Study in Healthy Male Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of AZD2820 After Single Ascending Doses
Study Start Date : May 2011
Actual Primary Completion Date : November 2011
Actual Study Completion Date : November 2011

Arm Intervention/treatment
Experimental: AZD2820 Drug: AZD2820
Subcutaneous Injection in abdomen or Thigh
Placebo Comparator: Placebo Drug: Placebo
Subcutaneous Injection in abdomen or Thigh

Primary Outcome Measures :
  1. Safety variables ( Adverse events, Vital signs, ECG, EEG, Regiscan, Safety labs.) [ Time Frame: Assessments performed multilpe times from the morning day 1 before dose until day 3. And then once at the follow up after 14-18 days ]

Secondary Outcome Measures :
  1. To evaluate the pharmacokinetics of AZD2820 and assess the dose proportionality of the pharmacokinetics following single ascending doses of AZD2820 by assessment Cmax, tmax, t1/2 , AUC, CL/F, Ae and CLR. [ Time Frame: Blood samples will be taken multiple times from the morning day 1 before dose until day 2 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of signed and dated, written informed consent prior to any study specific procedures.
  • Healthy male subjects aged ≥20 - ≤45 years with suitable veins for cannulation or repeated venepuncture.
  • Male subjects should be willing to use barrier contraception ie, condoms, from the day of dosing until 3 months after dosing with the investigational product.
  • Have a body mass index (BMI) between≥ 18 and ≤30 kg/m2 and weigh at least 50 kg and no more than 100 kg.
  • Provision of signed, written and dated informed consent for genetic research. If a subject declines to participate in the genetic component of the study, there will be no penalty or loss of benefit to the subject. The subject will not be excluded from other aspects of the study described in this Clinical Study Protocol, so long as they consent.

Exclusion Criteria:

  • History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study
  • History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs
  • A history of erectile dysfunction or anatomic abnormality of the penis (eg, cavernosal fibrosis, Peyronie's disease, or plaques) which interferes with normal erectile function
  • Predisposition or history of priapism (eg, sickle cell anemia or trait).
  • Any clinically significant illness, medical/surgical procedure or trauma within 4 weeks of the first administration of investigational product

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01332214

United Kingdom
Research Site
London, United Kingdom
Sponsors and Collaborators
Study Chair: Mirjana Kujacic, PhD AstraZeneca
Principal Investigator: Prof J Ritter BM BCh, MRCP, FRCP Quintiles, Inc.
Study Director: Mark Berner Hansen, PhD AstraZeneca

Responsible Party: AstraZeneca Identifier: NCT01332214     History of Changes
Other Study ID Numbers: D3870C00001
First Posted: April 11, 2011    Key Record Dates
Last Update Posted: November 21, 2011
Last Verified: November 2011

Keywords provided by AstraZeneca:
Phase 1
healthy male volunteers
dose escalation
Single Ascending Dose
AZD2820 Cmax